Compound or practice · Supplement
NMN
An NAD+ precursor with real biomarker effects (NAD+ rises) and no proven clinical or longevity outcomes yet.
- Overall grade
- Grade C
- Last revised
- 2
- graded outcomes
- 0
- references listed
A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.
1 at grade B · 1 at grade C — 2 graded rows
What is known
Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.
- Blood NAD+Evidence grade B
Reliably raised
Moderatehigh
- Physical function / insulin sensitivityEvidence grade C
Early, small
Smallmixed
What is uncertain
Read off the same rows as above. Nothing here is added that the entry does not itself record.
- Thin evidence: Physical function / insulin sensitivity (grade C).
The evidence in words
What it is
NMN is a precursor to NAD+, the coenzyme that declines with age and is central to energy metabolism and DNA repair.
How it works
Supplementation raises blood NAD+ and related metabolites, the premise being that restoring NAD+ counters aspects of aging.
What the evidence shows
Early human trials confirm NMN raises NAD+ and hint at modest improvements in physical function and insulin sensitivity in some groups — but hard outcomes and longevity effects are entirely unproven, and its regulatory status is contested. Interesting biomarker, unproven benefit.
How to use it
250–500 mg/day in trials; the field is early and product quality varies.
Safety & interactions
Appears well tolerated short-term; long-term safety uncharacterized.
Bottom line
It reliably raises NAD+, which is not the same as making you healthier or longer-lived. Promising biology, no proven payoff — an experiment, not an answer.
How it is used
As the entry records it, from the studies it summarises. Not a recommendation for you — doses that suit a trial population may not suit you.
- Standard
- 250–500 mg/day.
Related reading
Entries that share this one's tags or conditions.
- Nicotinamide RibosideThe better-studied NAD+ precursor — reliably raises NAD+, still short on hard human outcomes.Evidence grade C
- Nicotinamide Riboside for Blood NAD+Evidence grade A — Reliably raisedEvidence grade A
- Nicotinamide Riboside for Physical / metabolic functionEvidence grade C — InconsistentEvidence grade C
- Nicotinamide Riboside: dosage and how to take it300–1,000 mg/day.Evidence grade C
Sources
This entry lists no references of its own.
Last revised . A grade is this entry's reading of the evidence, not medical advice.